Acadia Healthcare Company, Inc. (ACHC)

In the past six months, several events have impacted Acadia Healthcare's stock price. Acadia Healthcare announced its fourth-quarter and full-year 2025 results, reporting Q4 revenue of $821.5 million, a 6.1% increase year-over-year, exceeding guidance, but also reported a net loss attributable to Acadia of $(13.02) per diluted share, primarily due to a non-cash goodwill impairment charge of $996.2 million. Debbie Osteen was appointed as CEO, leading to a stock increase. Acadia Healthcare updated its professional and general liability (PLGL) reserves, leading to a downward revision of its full-year 2025 Adjusted EBITDA and adjusted earnings per share guidance. Acadia Healthcare held its Q3 2025 earnings conference call, and while earnings beat estimates, management reduced forward guidance, causing the stock to sell off. Analysts have offered mixed outlooks, with a consensus "Hold" rating. The stock experienced a 52-week high of $31.04 and a 52-week low of $11.43, and as of March 30, 2026, the stock price was $22.83.

Demand for Acadia Healthcare's products and services generally benefits from strong, long-term tailwinds in the behavioral health sector. The first quarter typically experiences the highest startup costs and the lowest contribution from new beds, and supplemental payments can cause a "pretty big swing" between Q1 and the rest of the year. Despite quarterly fluctuations, the overall demand environment for behavioral health services remains consistent, particularly for higher acuity patients.

Acadia Healthcare Company, Inc. (ACHC) is a prominent American provider of for-profit behavioral healthcare services, operating within the Healthcare sector, specifically in the Medical Care Facilities and Psychiatric Hospitals industry. Acadia offers a comprehensive range of behavioral healthcare and substance use services through various facility types, including acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers (CTCs), residential treatment centers, and outpatient clinics. Acute inpatient psychiatric facilities are a significant contributor to the company's revenue in the United States.

Acadia Healthcare operates an extensive network of behavioral healthcare facilities across the United States and Puerto Rico. As of late 2024 and early 2025, the company managed approximately 262 facilities with around 11,850 beds in 39 states and Puerto Rico. In 2024, Acadia operated over 50 inpatient psychiatric hospitals in 19 U.S. states and 165 methadone clinics in 33 states, making it the largest methadone-clinic chain in the U.S.

Acadia Healthcare's brand reputation in the past year has been influenced by both positive recognition and challenges related to legal and financial matters. Seven Acadia facilities in five states were recognized in Newsweek's list of America's Best Addiction Treatment Centers for 2023. The company has faced ongoing legal and regulatory issues, including an SEC billing investigation, and settled a securities class action lawsuit for $179 million and incurred government-investigation-related costs. The significant increase in professional and general liability (PLGL) expenses also suggests potential reputational risks.

Acadia Healthcare Company, Inc. is primarily owned by institutional investors, holding approximately 120-121 million shares. Major Institutional Owners include Wellington Management Group LLP, BlackRock, Inc., Vanguard Group Inc., Khrom Capital Management LLC, FMR LLC, Goldman Sachs Group Inc., Deerfield Management Company, L.p. (series C), DME Capital Management, LP, and Jefferies Financial Group Inc. Key Individual Owners (Insiders) as of February 19, 2026, include Director Reeve B. Waud (712.97K shares), Director Debra K. Osteen (675.83K shares), and EVP and GC and Secretary Christopher L. Howard (371.25K shares). Insider ownership stood at 3.54% of outstanding equity.